There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Coherus Biosciences (CHRS) and Concert Pharma (CNCE) with bullish sentiments.
Coherus Biosciences (CHRS)
Mizuho Securities analyst Salim Syed maintained a Buy rating on Coherus Biosciences today and set a price target of $30.00. The company’s shares closed last Monday at $18.94.
According to TipRanks.com, Syed has 0 stars on 0-5 stars ranking scale with an average return of -4.8% and a 48.3% success rate. Syed covers the Healthcare sector, focusing on stocks such as Atara Biotherapeutics, Assembly Biosciences, and Unity Biotechnology.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Coherus Biosciences with a $30.00 average price target.
See today’s analyst top recommended stocks >>
Concert Pharma (CNCE)
Mizuho Securities analyst Difei Yang maintained a Buy rating on Concert Pharma today and set a price target of $13.00. The company’s shares closed last Monday at $6.18, close to its 52-week low of $5.47.
According to TipRanks.com, Yang has currently 0 stars on a ranking scale of 0-5 stars, with an average return of -4.7% and a 38.0% success rate. Yang covers the Healthcare sector, focusing on stocks such as Xeris Pharmaceuticals, Sarepta Therapeutics, and Magenta Therapeutics.
Concert Pharma has an analyst consensus of Strong Buy, with a price target consensus of $23.00.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
